Compare Davita Inc (DVA) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Lufax Holding Ltd — how do they compare? Davita Inc trades at $230.53 (market cap $14.92B), while Lufax Holding Ltd trades at $1.31 (market cap $2.41B). The key difference: Davita Inc is far larger — about 6.2× Lufax Holding Ltd's market cap, and Davita Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| DVA | LU | |
|---|---|---|
Market Cap | $14.92B | $2.41B |
Sector | Health | Technology |
52-Week High | $235.71 | $4.40 |
52-Week Low | $103.87 | $1.23 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
LU trades at $1.25, down 6.72% over 24 hours, with technical indicators signaling a bearish trend. The stock shows weak profitability with a -9.08% net margin and negative ROE of -2.6%, though valuation ratios like P/S of 0.33 and P/B of 0.1 appear low. Recent news highlights multiple class-action lawsuits filed against the company, alleging securities fraud between April 2023 and January 2025.
Outlook remains challenged by legal risks and poor earnings, but low valuations may attract speculative interest. Key risks include ongoing litigation and sustained unprofitability, while analyst consensus leans bullish with 62% buy ratings, suggesting potential recovery if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
